5-hydroxymethylcytosine has been researched along with 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; He, N; Hou, P; Ji, M; Jin, T; Liu, S; Liu, W; Qiang, W; Shi, B; Yang, Q | 1 |
1 other study(ies) available for 5-hydroxymethylcytosine and 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one
| Article | Year |
|---|---|
PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
Topics: 5-Methylcytosine; Aza Compounds; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cytosine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Mixed Function Oxygenases; Models, Biological; Mutation; Nuclear Proteins; Proto-Oncogene Proteins; Thyroid Neoplasms; Tumor Suppressor Protein p53; Up-Regulation | 2014 |